These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1718597)

  • 1. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor.
    Hori A; Sasada R; Matsutani E; Naito K; Sakura Y; Fujita T; Kozai Y
    Cancer Res; 1991 Nov; 51(22):6180-4. PubMed ID: 1718597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases.
    Gualandris A; Rusnati M; Belleri M; Nelli EE; Bastaki M; Molinari-Tosatti MP; Bonardi F; Parolini S; Albini A; Morbidelli L; Ziche M; Corallini A; Possati L; Vacca A; Ribatti D; Presta M
    Cell Growth Differ; 1996 Feb; 7(2):147-60. PubMed ID: 8822198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intraperitoneally, intravenously and intralesionally administered monoclonal anti-beta-FGF antibodies on rat chondrosarcoma tumor vascularization and growth.
    Coppola G; Atlas-White M; Katsahambas S; Bertolini J; Hearn MT; Underwood JR
    Anticancer Res; 1997; 17(3C):2033-9. PubMed ID: 9216661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Rofstad EK; Halsør EF
    Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action.
    Coltrini D; Gualandris A; Nelli EE; Parolini S; Molinari-Tosatti MP; Quarto N; Ziche M; Giavazzi R; Presta M
    Cancer Res; 1995 Oct; 55(20):4729-38. PubMed ID: 7553656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.
    Ensoli B; Markham P; Kao V; Barillari G; Fiorelli V; Gendelman R; Raffeld M; Zon G; Gallo RC
    J Clin Invest; 1994 Nov; 94(5):1736-46. PubMed ID: 7525646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
    Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
    Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
    Wang LL; Li JJ; Zheng ZB; Liu HY; Du GJ; Li S
    Eur J Pharmacol; 2004 Oct; 502(1-2):1-10. PubMed ID: 15464084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different antitumor activities of anti-bFGF neutralizing antibodies: heparin-binding domain provides an inefficient epitope for neutralization in vivo.
    Aonuma M; Yoshitake Y; Nishikawa K; Tanaka NG
    Anticancer Res; 1999; 19(5B):4039-44. PubMed ID: 10628351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.
    Inoue K; Perrotte P; Wood CG; Slaton JW; Sweeney P; Dinney CP
    Clin Cancer Res; 2000 Nov; 6(11):4422-31. PubMed ID: 11106263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
    Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
    Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of basic fibroblast growth factor in ovarian cancer growth and angiogenesis].
    Lin W; Peng ZL; Zheng A; Bi JH; Huang ZY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):532-5. PubMed ID: 14669225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
    Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
    Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.